Protocol Ledger

NCT04445987 · Phase II · COMPLETED

Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Interventional Phase II clinical trial protocol NCT04445987 sponsored by Arcutis Biotherapeutics in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-06-12 Enrollment: 408 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04445987
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)408 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04445987
Protocol FieldVerified Registry Value
NCT IdentifierNCT04445987
Consolidated Lead SponsorArcutis Biotherapeutics
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment408 participants (ACTUAL)
Registered Start Date2020-06-12
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI